SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-042515
Filing Date
2024-04-02
Accepted
2024-04-02 16:15:28
Documents
13
Period of Report
2024-04-01
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2410459d1_8k.htm   iXBRL 8-K 22064
  Complete submission text file 0001104659-24-042515.txt   196789

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA otlk-20240401.xsd EX-101.SCH 3316
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20240401_pre.xml EX-101.PRE 22381
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20240401_lab.xml EX-101.LAB 34240
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2410459d1_8k_htm.xml XML 3705
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 24814389
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)